Raymond James Downgrades Acceleron Pharma (XLRN) to Market Perform

Raymond James analyst Danielle Brill downgraded Acceleron Pharma (NASDAQ: XLRN) from Strong Buy to Market Perform.

For an analyst ratings summary and ratings history on Acceleron Pharma click here. For more ratings news on Acceleron Pharma click here.

Shares of Acceleron Pharma closed at $174.35 yesterday.

You May Also Be Interested In

• UPDATE: BofA Securities Downgrades Futu Holdings Limited (FUTU) to Underperform
• RBC Downgrades Morgan Stanley (MS) to Sector Perform but Stays Bullish Long-Term
• Semiconductor Stocks: Prepare for Mixed 3Q Results/Guidance Says Goldman Sachs and Upgrades Broadcom (AVGO) to Buy and Downgrades Western Digital (WDC) to Neutral